Viatris to acquire Pacira BioSciences for $1.65 billion
Viatris (VTRS) will acquire Pacira BioSciences (PCRX) for $1.65B, or $36.50 per share. The deal adds two patented drugs to Viatris' portfolio. Pacira reported $746M revenue and $177M adjusted EBITDA in the last 12 months. The transaction is expected to close by year-end 2026 and is immediately accretive to Viatris' financials, according to the companies.
How this was made
The 30-second read
Why it matters
The transaction is expected to be immediately accretive and funded primarily with cash, affecting both companies' share structures.
Market read
A $1.65 billion cash acquisition that will reshape Viatris' product lineup and remove Pacira from public markets.
What to watch
Regulatory approval timelines for the combined product portfolio may delay synergies.
Background
The article reports the first public disclosure of Viatris' definitive agreement to acquire Pacira.
Ticker impact
Viatris announced a $1.65 billion cash acquisition of Pacira BioSciences, immediately accretive to guidance.
likely upside as the market prices in the accretive acquisition and expanded pipeline
Accretive M&A of this size typically lifts the acquirer's stock on the day of announcement.
Pacira BioSciences is the target of Viatris' $1.65 billion cash tender offer, ending its Nasdaq listing.
likely pressure as the stock will be delisted and absorbed into Viatris
Tender offers usually drive the target's share price toward the offer price and then cease trading.
Market effects
strengthens the pharmaceutical pain‑management niche and may spur consolidation activity.
U.S. healthcare sector sees a notable M&A transaction.
large‑cap deal highlights ongoing consolidation in global pharma.
Counterpoint
If integration costs exceed expectations, the acquisition could weigh on Viatris' margins.
Key entities
- CompanyViatris Inc.
Acquirer, US‑listed pharmaceutical company.
- CompanyPacira BioSciences, Inc.
Target, US‑listed pharmaceutical company.
